Moderna, Inc. (MRNA)
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Moderna (MRNA) concluded the recent trading session at $49.56, signifying a -7.49% move from its prior day's close.
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day.
The S&P 500's 3 Best-Performing Stocks so far in 2026
Fear is dominating global markets right now. With geopolitical tensions intensifying in the Middle East and capital rotating out of equities, the S&P 500 ETF NYSEARCA: SPY is down about 2% year to date (YTD).
Moderna (MRNA) Declines More Than Market: Some Information for Investors
In the most recent trading session, Moderna (MRNA) closed at $52.56, indicating a -1.55% shift from the previous trading day.
Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot
Immatics (IMTX) remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline. IMTX's valuation reflects high expectations, with the PRAME franchise and next-generation assets like IMA402 representing key upside optionality. SUPRAME's mid-2026 interim update is a pivotal go/no-go catalyst, but unlikely to deliver a near-term stock-moving data readout.
Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom
Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP technology, ensuring freedom to operate for its infectious disease and vaccine pipeline, including future combo vaccines. The settlement preserves MRNA's strong balance sheet, with projected 2026 liquidity of $5.4–$5.9 billion, supporting pipeline expansion and breakeven target by 2028.
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.
Moderna to pay up to $2.25B to settle COVID vaccine patent matter
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock added almost 9% after it was announced that the drugmaker has agreed to pay up to $2.25 billion to settle a global patent infringement lawsuit brought by Arbutus Biopharma and Genevant Sciences over the use of lipid nanoparticle (LNP) delivery technology in its COVID-19 and RSV vaccines. The settlement resolves all US and international enforcement actions related to Moderna's use of Arbutus' and Genevant's LNP technology in Spikevax, its COVID-19 vaccine, and mRESVIA, its RSV vaccine.
Moderna and Ross Stores Lead Stock Gainers on Wednesday
Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct catalyst.
Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang
Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to focus on its pipeline.
Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline
The deal would provide ‘certainty' for Moderna's vaccine portfolio.
